Skip to content

Comparison of Conventional Dialysis and the Allient System

Uremic Toxin Removal, Blood Cell Kinetics, and Inflammatory Response in Patients Treated With the Allient System

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00788905
Enrollment
40
Registered
2008-11-11
Start date
2008-11-30
Completion date
2014-01-31
Last updated
2013-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Failure, End Stage Renal Disease

Keywords

Hemodialysis

Brief summary

The purpose of the study to determine whether the level of inflammation may be decreased, the lifespan of red blood cells increased and the clearance of waste products in the blood improved through the use of the Allient System as compared to conventional hemodialysis.

Interventions

DEVICEAllient System

The Allient System uses a different type of blood pump and a lower volume of dialysate.

Sponsors

Renal Solutions, Inc.
CollaboratorINDUSTRY
Renal Research Institute
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Maintenance in-center hemodialysis * Age greater than or equal to 18 years * Has been on hemodialysis for at least 4 months * Uses a standard single-pass dialysis machine with a high-flux dialyzer

Exclusion criteria

* Hospitalization during the 8 weeks preceding enrollment * Infection requiring antibiotic treatment during the 8 weeks preceding enrollment * Central venous cather as dialysis access * Uncontrollable blood coagulation anomalies * Smokers * Dialysis regimen other than 3 times weekly * In ability to understand the English language and give informed consent for participation in the study

Design outcomes

Primary

MeasureTime frame
Clearance of specific waste products from blood determined through subject blood and dialysate samples3 weeks

Secondary

MeasureTime frame
Inflammation as determined by levels of specific inflammatory markers3 weeks
Red blood cell lifespan determined through a measurement of CO in the subject's breath3 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026